Descrizione del progetto
Vaccini migliorati per la terza età
L’obiettivo del progetto ISOLDA, finanziato dall’UE, è quello di sviluppare nuovi vaccini contro le malattie virali dell’età avanzata incoraggiando le risposte delle cellule T virus-specifiche che colpiscono l’immunosenescenza e l’inflammaging delle cellule T. Un consorzio internazionale valuterà il potenziale degli immunomodulatori, tra cui gli inibitori di chinasi concessi in licenza per altre applicazioni, per migliorare le risposte immunitarie indotte dai vaccini. I composti migliori selezionati saranno testati utilizzando modelli animali in vivo per la vaccinazione contro le malattie virali. Come prova di concetto clinica, i ricercatori si concentreranno sul miglioramento dell’efficacia dei vaccini antinfluenzali applicando alle formulazioni dei vaccini attuali un composto guida immunomodulatore selezionato da studi ex vivo e in vivo. ISOLDA è inteso a fornire soluzioni innovative all’efficacia ridotta collegata all’età negli attuali vaccini preventivi contro le infezioni virali per la popolazione anziana in crescita.
Obiettivo
ISOLDA aims at the development of improved vaccines for older adults against viral diseases with highest burdens at old age, by promoting virus-specific T cell responses in vaccinees over 65 years, using modulators of T cell immunosenescence and inflammageing. It builds on leading interdisciplinary expertise and knowledge of ISOLDA partners in virology, (onco-)immunology, ageing and immunosenescence, to assess the potential of immunomodulators, including kinase inhibitors licenced for other human use, to improve vaccine-induced immune responses and safety in older adults. ISOLDA partners have shown that these compounds may indeed restore key immunosenescent signatures. They will investigate ex-vivo signatures of immunological ageing and restoring potential of selected compounds on vaccine-induced immune responses against influenza virus, using PBMC from past and on-going adult and ageing human cohorts of influenza vaccinees. Cohorts of vaccinees and/or patients for tick-borne encephalitis, Middle-East respiratory syndrome and yellow fever are also uniquely available to ISOLDA to demonstrate broad applicability of the approach. The most promising compounds will be tested in in-vivo animal models for vaccination against these diseases. As a clinical proof of concept, ISOLDA will aim at improving efficacy of current seasonal influenza vaccines up to a tiered phase I clinical trial with a lead immunomodulator compound selected from the ex vivo and in vivo studies, that will be added to current vaccine formulations. ISOLDA will further build on new generation vaccines against MERS, such as replication-competent propagation-deficient replicons and MVA-MERS S recently developed by ISOLDA partners. Taken together, ISOLDA will address call SC1-BHC-14-2019, by providing innovative solutions to reduced efficacy and safety of preventive vaccines in the increasing population of older adults, against viral infections that have the highest impact in this age group.
Campo scientifico
Parole chiave
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2019-Two-Stage-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
30559 Hannover
Germania